Serge Saxonov Sells 18,545 Shares of 10x Genomics (NASDAQ:TXG) Stock

10x Genomics (NASDAQ:TXG) CEO Serge Saxonov sold 18,545 shares of 10x Genomics stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $63.02, for a total transaction of $1,168,705.90. Following the transaction, the chief executive officer directly owned 1,085,835 shares in the company, valued at $68,429,321.70. This trade represents a 1.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Serge Saxonov also recently made the following trade(s):

• On Monday, June 22nd, Serge Saxonov sold 30,000 shares of 10x Genomics stock. The shares were sold at an average price of $34.44, for a total transaction of $1,033,200.00.

10x Genomics Price Performance

10x Genomics stock opened at $64.85 on Friday. The firm has a 50 day simple moving average of $47.62 and a 200-day simple moving average of $31.62. The stock has a market cap of $8.45 billion, a price-to-earnings ratio of -109.91 and a beta of 2.03. 10x Genomics has a 1-year low of $11.16 and a 1-year high of $66.94.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.10. 10x Genomics had a negative net margin of 12.18% and a negative return on equity of 9.33%. The firm had revenue of $151.04 million for the quarter, compared to analyst estimates of $146.67 million. During the same quarter in the previous year, the company earned $0.28 EPS. The business’s revenue for the quarter was down 12.7% compared to the same quarter last year. Equities analysts expect that 10x Genomics will post -0.75 earnings per share for the current fiscal year.

Institutional Trading of 10x Genomics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. purchased a new position in shares of 10x Genomics during the fourth quarter worth $38,000. Larson Financial Group LLC raised its holdings in shares of 10x Genomics by 164.4% in the 4th quarter. Larson Financial Group LLC now owns 2,364 shares of the company’s stock valued at $39,000 after buying an additional 1,470 shares during the period. Fifth Third Bancorp purchased a new stake in shares of 10x Genomics in the 1st quarter valued at $50,000. Elevation Wealth Partners LLC lifted its stake in 10x Genomics by 332.3% during the 2nd quarter. Elevation Wealth Partners LLC now owns 1,487 shares of the company’s stock worth $57,000 after acquiring an additional 1,143 shares in the last quarter. Finally, Van ECK Associates Corp lifted its stake in 10x Genomics by 85.9% during the 4th quarter. Van ECK Associates Corp now owns 3,668 shares of the company’s stock worth $60,000 after acquiring an additional 1,695 shares in the last quarter. Hedge funds and other institutional investors own 84.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on TXG. Stifel Nicolaus set a $50.00 price target on 10x Genomics in a research note on Friday, August 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of 10x Genomics in a research report on Wednesday, June 24th. Canaccord Genuity Group boosted their price objective on shares of 10x Genomics from $50.00 to $60.00 and gave the company a “buy” rating in a report on Monday, August 10th. Piper Sandler upped their target price on shares of 10x Genomics from $42.00 to $47.00 and gave the company a “neutral” rating in a research report on Monday, August 10th. Finally, Citigroup upped their target price on shares of 10x Genomics from $45.00 to $50.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Five analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $38.31.

More 10x Genomics News

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: Recent quarterly results offered some fundamental support: 10x Genomics reported an adjusted loss of $0.14 per share, better than the expected $0.24 loss, while revenue of $151.0 million exceeded estimates of $146.7 million. Several analysts subsequently raised their price targets, including Stephens to $65 and Canaccord Genuity to $60.
• Neutral Sentiment: CEO Serge Saxonov, CFO Adam Taich and insider Benjamin Hindson sold a combined approximately $3.12 million of shares. The transactions reduced their holdings by 1.68% to 4.52% and were reported as sales to cover tax obligations from vested equity awards, making them a less negative signal than discretionary insider selling. Each continues to hold a substantial position. Insider sales report CEO sale report
• Negative Sentiment: Director Shehnaaz Suliman sold 2,207 shares for approximately $140,476, reducing her direct ownership by 6.96%. The filing did not identify tax withholding as the reason, creating a modestly cautious insider signal. Director sale report
• Negative Sentiment: 10x Genomics remains unprofitable, with analysts expecting a full-year loss of approximately $0.75 per share. Revenue also declined 12.7% year over year in the latest quarter, while the consensus price target of $38.31 is substantially below the stock’s recent level, highlighting valuation and execution risk after its sharp rally.

10x Genomics Company Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.